ScreenerHero

GNLXGenelux Corporation Common Stock

NAS · US · Healthcare · Biotechnology · genelux.com
2.720USD+1.49%Mkt Cap: 123.07M $P/E: —

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap123.07M $
Enterprise Value107.72M $
Revenue (TTM)8.00K $
Gross Profit8.00K $
Net Income (TTM)-32.15M $
Revenue/Share0.0000 USD
Last Price2.720 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees25
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.78
PEG—
EV/EBITDA-2.97
EV/Revenue13465.28
P/S15496.53
P/B7.68
EPS (TTM)-0.88
EPS (Forward)-0.72
52W Range
2.2907% of range8.535
52W High8.535 USD
52W Low2.290 USD
Profitability
Gross Margin100.00%
Oper. Margin-455275.00%
EBITDA Margin0.00%
Profit Margin-401812.50%
ROE-278.46%
ROA-168.94%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-25.27M $
CapEx (TTM)1.10M $
FCF Margin-203671.88%
FCF Yield-13.24%
Net Debt-16.25M $
Net Debt/EBITDA0.45
Balance Sheet
Debt/Equity0.15
Current Ratio2.39
Quick Ratio2.33
Book Value/Sh0.3570 USD
Cash/Share0.4130 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)17.50 USD
Upside (mean)+543.4%
Target Range10.00 USD – 31.00 USD
$10.00+543.4% to mean$31.00
# Analysts6
Ownership
Shares Out.45.25M
Float36.80M
Insiders12.99%
Institutions31.01%
Short Interest
Short Ratio18.1d
Short % Float7.08%
Short % Out.6.88%
Shares Short3.08M
Short (prev mo.)3.01M
Technical
SMA 502.868 (-5.2%)
SMA 2003.256 (-16.5%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)252.79K
Avg Vol (10d)339.31K
Technical Indicators
RSI (14)46.6
MACD-0.0610
MACD Signal-0.0584
MACD Hist.-0.0026
BB Upper3.077 USD
BB Middle2.788 USD
BB Lower2.498 USD
BB Width20.80%
ATR (14)0.1724 USD
Vol Ratio (20d)0.64x